Programs Skin Lightening

 

Globally, there is a growing trend for lighter skin in many parts of the world.  Approximately 15% of the world population invests in skin lightening products and the global market is expected to reach US$23 billion by 2020. Asia is currently the largest market, with an estimated US$13 billion spent annually on skin lightening products. This trend includes both men and women as a 2012 survey showed that 80% of Indian men use fairness creams.

Demand for skin lighteners in North America and Europe has also been driven by a desire to reverse sun damage and for the appearance of younger looking skin.  Medical conditions such as hyperpigmentation, melasma, vitiligo and rosacea are also contributing to the demand for safer and more effective skin lightening creams.

There is a recognized need for a safer and more effective skin lightening agent.  The most common skin lightening agent worldwide is hydroquinone. While it is effective, hydroquinone is linked to cancer and has been banned in Europe since 2001.  In the United States, restrictions have been placed on concentration levels of hydroquinone; over-the-counter creams are restricted to no more than 2% hydroquinone and a prescription is required to obtain a maximum 4% hydroquinone concentration. Despite the dangers, restrictions and bans, hydroquinone is still widely used around the world. Other skin lightening agents (e.g. arbutin) have been banned due to their instability and subsequent breakdown into hydroquinone.

Sirona Biochem’s Skin Lightener

Sirona Biochem has developed a skin lightening agent which studies prove is safer and more effective than various well-known lighteners.
See Sirona Biochem’s latest business development presentation from the Innocos World Beauty Summit 2016.

The development program is directly supported by the French government. Recognizing the exceptional innovation of Sirona’s subsidiary, TFChem, the French government awarded the laboratory a $1.9M grant in 2011.  The grant is designed to bring the skin lightening program to a commercial-ready stage.  A cosmetic consortium, which includes the University of Rouen and contract research organization, Biogalenys, has also been established to support Sirona’s cosmetic programs.

Several studies have been conducted to demonstrate the effectiveness and stability of Sirona Biochem’s depigmenting agents, including TFC-1067.

Sirona Biochem’s studies were completed in accordance with the regulatory methods of the European Centre for the Validation of Alternative Methods (ECVAM) and the Organization for Economic Co-operation and Development (OECD).  No animals were involved in the development and testing of Sirona Biochem’s skin lightening compounds.

Skin Lightener Program Studies Completed
Skin Lightener Milestones Aug2016

Commercialization

In 2014, Sirona announced the formal execution of the global exclusive licensing agreement with Obagi Medical Products (Obagi) for the commercialization of skin lightening compound TFC-849. Sirona Biochem has received a licensing fee and will recieve ongoing royalty payments for global product sales from Obagi Medical Products.

Sirona’s other skin lightening compounds remain available for:

  • Licensing Agreements
  • Royalty Agreements
  • Acquisition of our technology
  • Joint ventures

For any additional information please contact Aleksandra Kasikovic at akasikovic@sironabiochem.com.

Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.